Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324291 | 1.00 | MAOB (0.40) | MAOBSIGMAR1TMEM97HMOX1CYP2C9 | |
| SCHEMBL4329255 | 1.00 | MAOB (0.40) | MAOBSIGMAR1TMEM97HMOX1CYP2C9 | |
| SCHEMBL13611870 | 1.00 | MAOB (0.40) | MAOBSIGMAR1TMEM97HMOX1CYP2C9 | |
| SCHEMBL4324287 | 1.00 | MAOB (0.40) | MAOBSIGMAR1TMEM97HMOX1CYP2C9 | |
| SCHEMBL4326985 | 0.90 | MAOB (0.46) | MAOBSIGMAR1TMEM97KDM4EGAA | |
| SCHEMBL4326990 | 0.90 | MAOB (0.46) | MAOBSIGMAR1TMEM97KDM4EGAA | |
| SCHEMBL4325230 | 0.90 | MAOB (0.46) | MAOBSIGMAR1TMEM97KDM4EGAA | |
| SCHEMBL4331977 | 0.90 | MAOB (0.46) | MAOBSIGMAR1TMEM97KDM4EGAA | |
| SCHEMBL4340441 | 0.88 | TMEM97 (0.42) | MAOBSIGMAR1TMEM97CYP2C9KDM4E | |
| SCHEMBL4338115 | 0.88 | TMEM97 (0.42) | MAOBSIGMAR1TMEM97CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | MAOB 2762/4885SIGMAR1 948/4885TMEM97 784/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | MAOB 3093/4885SIGMAR1 776/4885TMEM97 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.